Combined sarcomatoid hepatocellular and cholangiocarcinoma: a case report and literature review

Tsang, Jwh; Chok, Kenneth S. H.; Au-Yeung, Rex; Lo, CM

doi:10.4103/2394-5079.154331

Cited by 4 publications

(4 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The decision to treat ICC was driven by the predominance of the cholangiocarcinoma component, leading to the exclusion of atezolizumab plus bevacizumab, a treatment typically reserved for HCC. Previous case studies have reported greater success rates by directing treatment towards the dominant histology 33…”

Section: Discussionmentioning

confidence: 99%

Efficacy of dual checkpoint inhibitors in a patient with a mixed hepatocellular cholangiocarcinoma

Sucre,

Bullock,

Peters

2024

BMJ Case Rep

View full text Add to dashboard Cite

A woman in her 60s was diagnosed with a metastatic, unresectable rare histological type of liver cancer; combined hepatocellular cholangiocarcinoma. She had palliative chemotherapy, initially with gemcitabine and cisplatin, and then with oxaliplatin, L-folinic acid and fluorouracil. Both treatment strategies demonstrated disease progression, and somatic mutation profiling revealed no actionable mutations. The patient was started on immuno-oncology (IO) with nivolumab and ipilimumab, followed by maintenance nivolumab. She has achieved a sustained ongoing partial response since the start of this therapy for at least 12 months. The outcome in this patient is in keeping with the growing evidence of the role that IO agents have in metastatic biliary tract cancer and also serves to highlight their importance in mixed histology liver tumours.

show abstract

Section: Discussionmentioning

confidence: 99%

Efficacy of dual checkpoint inhibitors in a patient with a mixed hepatocellular cholangiocarcinoma

Sucre,

Bullock,

Peters

2024

BMJ Case Rep

View full text Add to dashboard Cite

show abstract

“…Chemotherapy may cause some treatment response; however, it does not prolong patient survival. Because of its rarity and the lack of clearly defined diagnostic criteria in the past, there are no standard systemic or locoregional therapies such as transarterial chemoembolization or radiation therapy for recurrent or metastatic cHCC-CCA 2,23,24 . In recent years, molecular targeted therapy for primary liver carcinoma has made remarkable progress, and the development of molecular targeted therapy for cHCC-CCA is expected in the future.…”

Section: Discussionmentioning

confidence: 99%

A Case Review on Combined Hepatocellular Cholangiocarcinoma

Kondo¹,

Akiba²,

Yano³

2022

AJSP: Reviews and Reports

View full text Add to dashboard Cite

Combined hepatocellular-cholangiocarcinoma (cHCC-CCA) is a rare primary liver tumor with neoplastic components of both hepatocytic and cholangiocytic differentiation within the same tumor, such as the case reported herein. There is a need to standardize the pathological diagnosis of cHCC-CCA and to improve the concordance of diagnosis among pathologists based on consensus paper because of its histological and phenotypic diversity that leads to confusion in terminology and classification. This case review addresses the terminology, classification, and clinical and pathological characteristics of cHCC-CCA and its differential diagnosis.

show abstract

“…Because no specific evidence-based treatment for cHCC-iCCA has been established [130,131], advanced cHCC-iCCA is often treated similar to HCC or, more often, as iCCA [5,[132][133][134][135]. Rogers et al have reported a clinical benefit in 3 cases of patients with unresectable cHCC-iCCA treated with gemcitabine (gem)-platinum with or without bevacizumab (bev) [136] (Table 3).…”

Section: Systemic Treatmentmentioning

confidence: 99%

Combined Hepatocellular-Cholangiocarcinoma: Biology, Diagnosis, and Management

Schneider¹,

Khaled²,

Schirmacher³

et al. 2023

Liver Cancer

View full text Add to dashboard Cite

Background Combined hepatocellular-cholangiocarcinoma (cHCC-iCCA) is a rare type of primary liver cancer displaying characteristics of both hepatocytic and cholangiocytic differentiation. Summary Because of its aggressive nature, patients with cHCC-iCCA exhibit a poorer prognosis than those with HCC. Surgical resection and liver transplantation may be considered as curative treatment approaches; however, only a minority of patients are eligible at the time of diagnosis and postoperative recurrence rates are high. For cases that are not eligible for surgery, locoregional and systemic therapy are often administered based on treatment protocols applied for HCC or iCCA. Owing to the rarity of this cancer, there are still no established standard treatment protocols; therefore, the choice of therapy is often personalized and guided by the suspected predominant component. Further, the genomic and molecular heterogeneity of cHCC-iCCA can severely compromise the efficacy of the available therapies. Key Messages In the present review, we summarize the latest advances in cHCC-iCCA and attempt to clarify its terminology and molecular biology. We provide an overview of the etiology of cHCC-iCCA and present new insights into the molecular pathology of this disease that could contribute to further studies aiming to improve the patient outcomes through new systemic therapies.

show abstract

Combined sarcomatoid hepatocellular and cholangiocarcinoma: a case report and literature review

Cited by 4 publications

References 15 publications

Efficacy of dual checkpoint inhibitors in a patient with a mixed hepatocellular cholangiocarcinoma

Efficacy of dual checkpoint inhibitors in a patient with a mixed hepatocellular cholangiocarcinoma

A Case Review on Combined Hepatocellular Cholangiocarcinoma

Combined Hepatocellular-Cholangiocarcinoma: Biology, Diagnosis, and Management

Contact Info

Product

Resources

About